Business
Cipher Reports 30% Revenue Growth and 40% Adjusted EBITDA Growth in Second Quarter of 2021, Driven by Strength in Epuris and Absorica
Cipher Reports 30% Revenue Growth and 40% Adjusted EBITDA Growth in Second Quarter of 202...
About this update from Cipher Pharmaceuticals Inc.
[{"type":"text","content":"\n \n \n \n Cipher Reports 30% Revenue Growth and 40% Adjusted EBITDA Growth in Second Quarter of 2021, Driven by Strength in Epuris and Absorica\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prngen2{\nBORDER-TOP:black 0pt; BORDER-RIGHT:black 0pt; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM:black 0pt; TEXT-ALIGN: RIGHT; PADDING-LEFT:0.50em; BORDER-LEFT:black 0pt; PADDING-RIGHT:0.50em\n}\n.prngen3{\nBORDER-TOP:black 0pt; BORDER-RIGHT:black 0pt; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM:black 0pt; PADDING-LEFT:0.50em; BORDER-LEFT:black 0pt; PADDING-RIGHT:0.50em\n}\n.prnsbt0{\nBORDER-TOP:0pt\n}\n.prnsbr0{\nBORDER-RIGHT:0pt\n}\n.prnbcc{\nBORDER-COLLAPSE: COLLAPSE\n}\n.prnsbl0{\nBORDER-LEFT:0pt\n}\n.prnsbb0{\nBORDER-BOTTOM:0pt\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n \n Revenue increases 30% to\n \n $6.1 million\n \n , Adjusted EBITDA\n \n 2\n \n increases 40% to\n \n $4.1 million\n \n \n \n \n \n EPS increases 450% to\n \n $0.11\n \n (\n \n CDN$0.14\n \n \n 1\n \n )\n \n \n \n \n Epuris revenue grows 63%, Absorica revenue grows 25%\n \n \n \n \n All figures in U.S. dollars, unless otherwise noted\n \n \n \n \n \n OAKVILLE, ON\n \n ,\n \n Aug. 12, 2021\n \n /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (\"\n \n Cipher\n \n \" or \"\n \n the Company\n \n \") today announced its financial and operating results for the three and six-months ended June 30, 2021. Unless otherwise noted,\n \n all figures are in U.S. dollars.\n \n \n \n \n \n Q2 2021 Financial Highlights\n \n \n \n \n (All figures in U.S. dollars, compared to Q2 2020, unless otherwise noted)\n \n \n \n \n Total revenue increased 30% to\n \n $6.1 million\n \n compared to\n \n $4.7 million\n \n \n \n SG&A decreased 10.3% to\n \n $1.2 million\n \n compared to\n \n $1.3 million\n \n \n \n Adjusted EBITDA increased 40% to\n \n $4.1 million\n \n compared to\n \n $2.9 million\n \n \n \n Earnings per common share increased 450% to\n \n $0.11\n \n compared to\n \n $0.02\n \n \n \n As at\n \n June 30, 2021\n \n the company had\n \n $16.1\n \n \n (CDN$19.9) million\n \n in cash or\n \n $0.60\n \n per share\n \n (CDN$...